Synergistic combination of immunologic inhibitors for the treatment of cancer
US10034939B2 · kind B2 · utility
3Cited by
9References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 25, 2013 |
| Grant date | Jul 31, 2018 |
| Priority date | — |
| Expiry date | Oct 25, 2033 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/507
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
In some embodiments, the methods involve the use of a combination of at least two of the following: an inhibitor of indoleamine-2,3-dioxygenase (IDO), an inhibitor of the PD-L1/PD-1 pathway, an inhibitor of CTLA-4, an inhibitor of CD25, or IL-7. The inventors particularly observed a major synergistic effect of combining anti-CTLA-4 with either an IDO inhibitor, with anti-PD-L1 mAb, or with CD-25 depletion. Such combinations have been found to demonstrate a synergistic effect in treating cancer and tumors, for example by reducing tumor size, increasing the percentage of antigen-specific T cells, and increasing T cell function.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.